Introduction
The T-cell receptor (TCR) expressed on a mature a/b T cell is composed of a heterodimer of genomically rearranged a-and b-chains generated through V(D)J somatic recombination with the addition/subtraction of nontemplated bases at recombination junctions that are fused in frame to constant (C) regions (1) (2) (3) (4) . The variable (V) regions contain 3 hyper variable complementarity-determining regions (CDR1, CDR2, and CDR3) that confer T-cell specificity via the recognition of small peptide antigens (8-12 mer) in the context of MHC proteins (1) . The CDR3 sequences of V regions are highly polymorphic and largely determine ability of T cells to recognize peptide antigen. CDR3 is unique to each rearranged TCR on a T-cell clone and thus TCRVa-and Vb-chain genes can be identified within families based on the shared sequences in hinge regions flanking the unique CDR3 sequences in the a-and b-chains (1, 2). Currently, there are 45 TCRVa-and 48 TCRVb-chains isolated and sequenced from the human genome (www.imgt.org/) which pair to form a mature and functional ab TCR (2, (5) (6) (7) . Methods to assess TCR diversity/usage within a T-cell population include (i) sequencing of CDR3 regions from TCRVb genes (5, (8) (9) (10) (11) , ( ii) spectratyping to analyze polymorphisms in length of CDR3 within Vb family (5, (12) (13) (14) , and (iii) flow cytometry using monoclonal antibodies to identify cell surface expression of TCRVb-chains (15) . Up until now, analysis of TCR clonotype has generally relied on PCR-based amplification of the DNA sequences that incorporate the CDR3 region using primers recognizing conserved Vb sequences flanking the CDR3 (2, 5, 6, 8, 9) . This has been referred to as Vb clonotyping. Methods to amplify and sequence CDR3 regions from Va genes have been less commonly used.
Changes in the TCR usage, including a skewing towards monoclonality or oligoclonality can be desired, such as the emergence of T cells with therapeutic potential after vaccination and adoptive transfer (9, 10, 13, 16, 17) , or unwanted as associated with inborn errors such as DiGeorge syndrome and severe combined immunodeficiency syndromes, autoimmune disease, infection, chronic inflammation, aging, and cancer (8-10, 12, 13, 18-22) . In particular, investigators have described adoptive transfer of tumorinfiltrating lymphocytes (TILs) into patients with metastatic melanoma that result in emergence of T cells in peripheral blood identified as expressing a subset of TCRVb-chains found in the original infusion product and this skewing is linked to superior antitumor response rates (9, 10, 17, (23) (24) (25) . Thus, the serial assessment of TCRVb diversity has been successfully used to evaluate the persistence and inform on the therapeutic potential of transferred TILs (9, 10) .
To reveal the complexity of TCR diversity, investigators have sequenced CDR3 rather than measuring their length. Massively parallel sampling of TCR usage by sequencing unique Vb CDR3 enzymatically amplified amplicons has identified clonotypes within T-cell pools (6, 7, 26) . This approach to profiling TCR sequences reveals the nucleotide sequences that compose the diversity and length of CDR3, but has been primarily undertaken within TCRVb family due to higher sequence variation at the Va loci (11) , as well as the downstream expense and time needed for acquisition and bioinformatics to analyze data. As an alternative to profiling T-cell Vb metagenomes by highthroughput sequencing, cloning and sequencing of TCRVb genes can be undertaken, despite that this method is laborious and time-consuming (8) (9) (10) 20) . However, low frequency, yet potentially clinically important T-cell populations may not be detected by this approach, as only a limited number of bacterial clones carrying TCRVb gene inserts can be isolated and sequenced. Furthermore, this approach has been limited to analyzing the TCRVb diversity and not patterns of Va usage. Therefore, a practical and sensitive alternative method that can rapidly measure or screen for the expression frequencies of all TCRVa and Vb transcripts in heterogeneous populations of T cells is warranted.
Here, we report a new nonenzymatic approach to directly analyze TCR diversity using a method that directly identifies and measures the frequency of both TCRVa and Vb gene expression in RNA isolates or cell lysates without the need for PCR (including 5 0 RACE) and gene cloning. The DTEA uses the nCounter assay system (NanoString Technologies, Seattle, WA). This system uses panels of multiple fluorescently tagged (bar-coded) probes that specifically bind mRNA transcripts (without the enzymatic amplification of RNA) in a small number of cells or RNA, making possible the digitalization of gene expression (27) . In the current study, we designed custom probes to identify 45 Va and 46 Vb TCR genes present in the human genome. We evaluated the applicability of DTEA to serially measure changes in TCR gene expression profiles before and after adoptive transfer of ex vivo-propagated TILs by serially sampling the peripheral blood of patients with metastatic melanoma. We validated DTEA by comparing it with TCRVb gene cloning/sequencing and found that DTEA yielded reproducible results that reliably identified changes in the TCR usage in a highly sensitive manner over time, and observed a high degree of concordance between DTEA and TCRVb cloning/sequencing. However, low frequency clonotypes not detected using Vb cloning/sequencing could be identified and tracked by DTEA. In aggregate, DTEA provides a rapid, accurate, and sensitive global view to quantify the 45 TCRVa and 46 TCRVb transcripts in a T-cell population.
Materials and Methods

Samples for TCR analyses
TILs and peripheral blood mononuclear cells (PBMC) samples were obtained from 14 patients after informed consent at The University of Texas MD Anderson Cancer Center who had stage IIIc-IV metastatic melanoma and were participating in a U.S. Food and Drug Administration (FDA)-approved phase II T-cell therapy clinical trial (IND# BB-IND 12192, Institutional Review Board protocol 2004-0069) evaluating the efficacy of numerically expanded autologous TILs. The detailed information of this clinical trial was described in http://www.cancer.gov/clinicaltrials NCT00338377. TILs harvested from surgically resected visceral metastatic lesions were initially expanded with highdose interleukin-2 (6,000 IU/mL), and then subjected to a 2-week rapid expansion protocol to generate the final autologous TIL product used for infusion. Before TIL infusions, patients were treated with cyclophosphamide (60 mg/kg) and fludarabine (25 mg/m 2 ) to render recipients lymphopenic. After TIL infusions, peripheral blood samples were obtained from patients at 2 weeks, 1 month, 5 to 6 months, and 11 to 12 months (24, 25) . The PBMCs were then isolated using Ficoll-Hypaque, and 5 Â 10 6 PBMCs or TILs were lysed in RNeasy buffer (Qiagen, catalog #74104) for RNA isolation. Altogether, 18 TIL samples and 25 PBMC samples were serially collected after TIL infusions from 14 patients participating in the clinical trial and all were analyzed by both DTEA and sequencing (Supplementary Table S1 ).
Translational Relevance
Changes in TCR transcriptome are linked with both the efficacy of immunotherapy and the pathogenesis of various human diseases, such as DiGeorge syndrome, severe combined immunodeficiency syndromes, autoimmune disease, infection, chronic inflammation, aging, and cancer. Therefore, the development of a direct approach to track and measure the TCRVa and Vb gene usages in a heterogeneous mixture of T cells is valuable for assessing the therapeutic potential of adoptive immunotherapy and understanding pathology associated with skewed TCR expression. To this end, we developed the "Direct TCR Expression Assay" (DTEA) as a sensitive, rapid, reliable, and high-throughput digital technique to directly quantify both TCRVa and Vb transcripts in a single reaction using a small number of T cells or total RNA.
TCRVb gene cloning and sequencing
Total RNA was isolated from TILs and PBMCs using an RNeasy Kit and treated with DNase to remove genomic DNA contamination (Qiagen), and the quality of the RNA preparation was validated by agarose gel electrophoresis. To clone TCRVb transcripts, the SMARTer RACE cDNA amplification kit (5 0 RACE, Clontech, catalog #634924) was used as described previously (9, 10, 17) . Briefly, 1 mg total RNA was used to generate full-length cDNA using 5 0 -RACE CDS primer (provided in the kit), and the 5 0 adaptor (SMARTer II A primer) was then incorporated into each cDNA according to manufacturer's instructions. The TCRVb-specific cDNA was then amplified by PCR using a 3 0 primer (5 0 -CGA GGT AAA GCC ACA GTC-3 0 ) that binds to the constant region of both C1 and C2 of the TCRVb genes and a 5 0 primer (provided in the kit) that is complement to the adaptor sequence. The resulting TCRVb-specific PCR products were purified from the agarose gel and subcloned into the TA cloning vector TOPO4 (Invitrogen). Plasmid DNA was prepared from 96 bacterial colonies using Direct Prep96 BioRobot kit (Qiagen, catalog #96234). These 96 plasmid DNA isolates were further confirmed by PCR using primers that nested to TCR constant region (5 0 -TCTGATGGCT-CAAACACAG-3 0 ) and nested to the 5 0 adaptor (Nested Universal Primer A, NUP; 5 0 -AAGCAGTGGTATCAACGCA-GAGT-3 0 ) provided by manufacturer. Finally, the TCR-positive clones (usually 60-96 DNA plasmid isolates) were subjected to DNA sequencing at the core facility of MD Anderson Cancer Center (Houston, TX). These sequencing data were analyzed using the international IMGT (ImMunoGeneTics) information system (http://imgt.org/) to characterize the individual TCRVb clones.
DTEA to quantify TCRVa and Vb gene expression
The IMGT database (http://imgt.org/) was also used to identify TCRVa and Vb sequences and customized probes for 45 Va and 46 Vb families, which were designed and manufactured as an nCounter Gene Expression Assay Kit (NanoString Technologies). Because of 100% cross-hybridization between TCRVa8-2 and TCRVa8-4, the latter was omitted from the panel. Similarly, TCRVb6-3 and Vb12-4 were also omitted from the panel because of 100% crosshybridization with Vb6-2 and Vb12-3. Thus, only 45 of 46 TCRVa and 46 out of 48 TCRVb family members could be selected for the analysis. These TCRVa and Vb code sets and the housekeeping control genes are listed in Supplementary  Tables S2, S3 , and S4. Target molecules were detected according to hybridization to capture reporter sequences, each approximately 50 nt in length, that targeted a contiguous 100-bp sequence in each of the Va and Vb mRNA species. Target regions were screened against the RefSeq database to exclude direct and inverted repeat elements and evaluated to eliminate cross-hybridization. Each color-coded barcode is attached to a single target-specific reporter probe corresponding to a gene of interest as described previously (27) . Bar-coded probes, each 50 bp in length, were selected for melting temperatures between 78 C to 83 C. Hybridizations for each sample were set up as follows:
5 mL (100 ng) of total RNA, 10 mL of hybridization buffer, 10 mL of reporter probes, and 5 mL of capture probes that were mixed in PCR tubes and incubated at 65 C for 12 to 18 hours in a thermal cycler with a heated lid (Pelletier, BIO-RAD DNA Engine). After hybridization, the samples were processed in an nCounter PrepStation and counted using an nCounter Digital Analyzer (model no. NCT-SYST-120; NanoString Technologies). The processing and counting steps were fully automated and required no user interaction
Detection limit of TCRVa and Vb by DTEA
To determine the sensitivity of DTEA, DMF5 cells were serially diluted in Jurkat cells to assess the minimal cell numbers that were required for detecting both TCRVa and TCRVb expression. DMF5 is a primary human CD8 T-cell clone generated from melanoma TILs and coexpresses TCRVa12-2 and TCRVb6-4 (28). The DMF5 T-cell line was sorted with a fluorescence-activated cell sorter based after CD8 and Mart-1 tetramer (Beckman Coulter) staining to obtain more than 95% CD8 expression and Mart-1 tetramer-positive expression. Jurkat is a human acute lymphoblastic leukemia T-cell line that expresses TCRVb7-2 and apparently several TCRVa genes, including TCRVa18, 19, and 8-2 (all measured by DTEA from this work). Serial dilutions of DMF5 were spiked into Jurkat cells, resulting in a final DMF5 cell concentration ranging from 0.001% (1 DMF5 cell in 10 5 Jurkat cells) to 10% (10 4 DMF5 cells in 9 Â 10 4 Jurkat cells). A total of 10 5 cells were then lysed in 5 mL RNeasy lysis buffer (RLT) buffer from RNeasy Mini Kit (Cat # 74104, Qiagen) and used for DTEA assay with the same conditions used to determine TCRVa and TCRVb expression in total RNA of TILs and PBMCs.
Statistical analysis
To determine the reproducibility of DTEA, TIL RNA samples from 3 patients were analyzed and each RNA sample was run in triplicates. Gene expression data was analyzed according to nCounter data analysis guidelines. To obtain "specific hybridization counts" for the positive spike controls, housekeeping genes, and test genes, the average of the negative spike control counts in each lane was subtracted from that of the raw positive control counts, housekeeping genes counts, and test genes counts, respectively. Specific test gene hybridization counts in each lane were then normalized to both the positive control and housekeeping genes by the following formula: (test gene-specific hybridization counts Â positive spike control normalization factor Â housekeeping genes normalization factor). Normalization factors for the positive control and housekeeping genes in each lane were derived using the following formula: (sum of average counts/lane-specific sum of counts). Following normalization, triplicate measurements for each gene in each sample were averaged and SD and coefficient of variation (% CV) was determined. To calculate % CV, SD of the set of replicate measurements was divided by average value for those replicates (29, 30) . Coefficient variation (CV) and median CV for these samples were analyzed in Microsoft Excel version 2007.
Results
Reproducibility and sensitivity of DTEA to detect patterns of TCRVa and Vb usage DTEA should be capable of simultaneously assessing the expression of both TCRVa-and Vb-chains in a mixed T-cell population and this was tested in triplicate using TILs from 3 patients (253, 303, and 232) participating in a T-cell therapy clinical trial (Fig. 1A and B and Supplementary Fig. S1 ). Variations in the measured transcript numbers of individual TCRVa and Vb genes in these TIL samples ranged from 12% to 21% (median CV for TIL253 was 12%, TIL303 was 20%, and TIL232 was 21%). To address reproducibility between probe batches, the DTEA assay was conducted on a single RNA sample (TIL152) using 2 different lots of Vb probes. These experiments yielded similar results in terms of the spectra and quantities of detected TCRVb genes (Fig. 1C) . These data show that the variation associated with detecting TCR transcripts is minimal (29) .
To assess the minimal number of T cells needed to detect TCRVa and Vb usages, the T-cell clone DMF5, which expresses different TCRVa and Vb than Jurkat cells, was spiked with Jurkat cells at different ratios and subjected to the DTEA assay. A total of 10 5 cells were used in each DTEA reaction. The assay was conducted in 2 independent experiments. As shown in Fig. 1D and E, the mRNA levels coding for TCRVa12-2 and TCRVb6-4 varied in a linear fashion and proportional to the dilution of the DMF5 clone (P < 0.0001 in both cases). The limit for detecting the DMF5-specific TCRVa12-2 and TCRVb6-4 expression from the diluted samples was 0.1% (approximately 100 DMF5 in $10 5 Jurkat cells).
DTEA can detect the same pattern of TCRVb usage as cloning and sequencing of CDR3s
A side-by-side analysis of TCRVb gene expression comparing DTEA versus classical TCR gene cloning/sequencing in TILs from patient 228 revealed that DTEA detected all of the TCRVb clones that were identified by TCR gene cloning/ sequencing, as well as additional TCRVb genes undetectable by cloning/sequencing. Both DTEA and TCR gene cloning/ sequencing identified the major TCR clonotypes, TCRVb11-2 and Vb4-3. The calculated frequencies for TCRVb11-2 and Vb4-3 were similar for DTEA (54% and 18%; Fig. 2A) , and TCR gene cloning/sequencing (57% and 24%; Fig. 2C ). In contrast, the minor clonotypes TCRVb20-1 and Vb28 were detected at a frequency of 7% and 5.3%, respectively, using DTEA ( Fig. 2A ), but at a frequency of only 1.2% and 0% using the cloning/sequencing (Fig. 2C) methodology. Both TCRVb12-3 and Vb 6-2 were detected at a frequency of 1.15% by gene cloning, but only 0.47% and 0.35% by DTEA ( Fig. 2B and D) . This difference may be due to sampling error stemming from the limited number of TCR clones analyzed by cloning (usually 60-96 clones for each sample), which results, in this case, in an overestimation Table S5 ). These data show that DTEA not only detects the same TCR clonotypes as a TCR cloning/sequencing technique but also seems to be more sensitive and less prone to missing TCRVb transcripts that are present at low frequencies.
Tracking changes in levels of TCRVa and Vb transcripts after TIL adoptive transfer
To determine whether DTEA could be used to track T-cell persistence and variations in the TCR usage (e.g., numeric expansion or contraction of T-cell clones) in patients after TIL infusions, we compared results obtained using TCR cloning/sequencing and DTEA assays from PBMCs obtained at different times following TIL transfer (Fig. 3) . Both methods revealed a similar pattern of TCRVb gene expression in patients' PBMCs over time. The same dominant TCRVb transcripts were identified by both methods with some minor differences in the frequencies of TCRVb gene expression at certain time points (Fig. 3C) . To further assess whether DTEA can monitor changes in TCR gene usage, associated with infusion of TIL, we serially followed both TCRVa and TCRVb gene expression in 6 patients following adoptive immunotherapy. As shown in Supplementary Figs. S2-S7, DTEA could track the persistence and changes of the original pattern of TCR usage exhibited by the infused TIL when measured over time in patients' peripheral blood.
Tracking low frequency TCRVa and Vb usage in T cells by DTEA after TIL-adoptive transfer
To quantity the magnitude of TCR clonotypes not detected by TCR cloning/sequencing, but identified using DTEA, we tested samples obtained from TILs and peripheral blood collected before and after infusion for TCRVb genes expression using both methodologies. The results are summarized in Fig. 4 and Supplementary Table S5 . TCR gene cloning/sequencing detected only 6 and 12 different clonotypes in TIL228 and in TIL231, respectively. In contrast, DTEA of the same samples revealed the expression of 30 additional TCR clonotypes in TIL228 and 22 additional TCR clonotypes in TIL231, with frequencies ranging from 0.005% to 6.7% (Supplementary Table S5 ). TCRVb gene cloning/sequencing could not detect a number of low expression Vb transcripts, such as Vb14 (patient 152), and Vb19, or Vb24 (patient 172) in the initial TIL inocula or peripheral blood samples shortly after the infusion (Fig. 4) . Tracking of TCRVb gene usage for longer time intervals after TIL infusion found that while TCR gene cloning/sequencing detected TCRVb14 (3.2% frequency, patient 152) and TCRVb19 (1.36% frequency, patient 172), at only 11 and 5 months, DTEA detected these Vb transcripts already in the initial TIL infusion sample and at earlier time points following administration ( Fig. 4A and B) . Similar results were seen with TCRVb24 (Fig. 4C ). This suggests that some of the expanding or emerging T-cell clones in the peripheral blood of patients who have undergone TIL transfer may arise from a low frequency pool of T-cell clones that were undetectable by the classical TCR gene cloning/sequencing method. In aggregate, these results indicate that DTEA Overall, the 2 methods yielded similar TCRVb gene expression frequency patterns, although substantial differences in frequencies (up to 36%) between the 2 methods was observed at some points, as seen with TCRVb28 in peripheral blood obtained from patient 172 at 2 months (C).
is more sensitive compared with cloning/sequencing in detecting rare TCR gene usage.
Simultaneous tracking of TCRVa and Vb gene usage before and after TIL infusion
To further test the use of DTEA, we used DTEA to simultaneously track TCRVa and Vb expression in TIL and PBMC samples at different times following TIL infusion. As shown in Fig. 5 , we were able to concurrently determine TCRVa22 (45.15% frequency) and Vb4-3 (44.17% frequency) representing 2 of the highest expressing TCRVa and Vb clonotypes in TIL172 (Fig. 5A and B) . A similar result was obtained using PBMCs 2 weeks after infusion from patient 117, such that the most frequent TCR clonotypes were TCRVa13-2 (85.12%) and Vb7-2 (82.35%; Fig. 5D and E). For both patient samples, the frequency of other TCR clonotypes was at least 30% and as much as 7-fold lower. These results suggest that TCRVa22 and TCRVb4-3 (in patient 172) or TCRVa13-2 and TCRVb7-2 (in patient 117) may be paired in the same T cells. Further supporting our hypothesis was the observation of overlapping expression patterns for TCRVa22/Vb4-3 and TCRVa13-2/Vb7-2 in all PBMC samples obtained from patients 172 and 117, respectively ( Fig. 5C and F) . Moreover, CDR3 sequence analysis obtained using TCR cloning/sequencing identified only a single T-cell clone expressing TCRVb4-3 or TCR Vb7-2 in TIL172 and in PBMC117, respectively. Given our results with TIL172 and PBMC117, we extended our DTEA multiplex analysis to samples from patients 231, 228, and 106 (Supplementary Table S6 ). For TIL 231 TCRVa38-2 (17.15%), TCRVa14 (25.31%), TCRVb7-8 (18.76%), and TCRVb-13 (27.89%) were most highly represented, which on the basis of similar frequencies, suggests pairing of TCRVa38-2 with Vb7-8, and TCRVa14 with Vb-13 (Supplementary Table S6 ). In some samples, we observed a larger variation in major TCRVa and Vb expression, such as TCRVa29 (13.76%) and TCRVb9 (42.82%) in TIL 106, suggesting that the sample contained more than one TCRVb9 clonotypes, each presumably pairing with a different Va-chains (Supplementary Table S6 ). Overall, these results suggest that DTEA may be able to predict TCR ab-chain pairing for a particular T-cell clone within an oligoclonal population when there is significant enrichment of this clone and when the measured TCRVa-and Vb-chains are detected at similar frequencies.
Discussion
DTEA seems to be a sensitive, fast, and reliable highthroughput digital technique to directly quantify both TCRVa and Vb usage in a single nonenzymatic reaction using a small number of cells (100 target T cells) or as little as 100 ng total RNA. Currently, the cost runs about $1 to $1.25 per gene per sample or about $91 to $114 to survey the direct level of expression of all 45 TCRVa and 46 TCRVb genes in a sample. Using T-cell samples recovered from patients with melanoma that had received autologous ex vivo-propagated TILs, we observed that DTEA could be successfully used to (i) measure TCR Va and Vb usage and diversity and (ii) track low frequency T-cells in TIL and emerging in peripheral blood following adoptive immunotherapy. There was a high degree of concordance between DTEA and classical TCRVb gene cloning/sequencing for measuring the frequency of TCRVb transcripts when present at high abundance. However, DTEA was superior at identifying low frequency TCRVb (and presumably Va) transcripts, which is a major advantage over the TCR cloning/ sequencing method.
Measuring a broad complement of TCR chains can inform on the therapeutic potential of infusions of heterogeneous mixtures of tumor-specific T cells propagated ex vivo (23, 24, 28, (31) (32) (33) (34) . The antitumor effect of adoptive immunotherapy can be gauged by longitudinally tracking the infused T cells identified by measuring TCRVa and Vb genes expression profiles. Currently available methods for measuring TCR diversity are primarily limited to TCRVb usage and are based on (i) detection by flow-cytometry using antibody panel against TCRVb, (ii) CDR3 length spectratyping by semiquantitative reverse transcriptase PCR (RT-PCR), (iii) cDNA sequencing of the rearranged CDR3 regions, and (iv) deep sequencing of PCR-amplified rearranged genomic TCRVb genes. Although these approaches can detect oligoclonal expansions of T cells, in aggregate, they are labor-intensive, can be costly, require relatively long preparation as well as assay and analysis times, depend on availability of detection antibodies, and can require substantial amount of samples (9-11, 14, 15, 35) . In contrast, DTEA uses a panel of bar-coded probes to directly quantify 45 Va and 46 Vb mRNA species in a multiplexed assay so that changes in the diversity of both Va and Vb TCR chains can be simultaneously assessed in a highly sensitive, reproducible, and rapid fashion. DTEA is a direct measurement of the number of RNA transcripts found in the starting material (RNA or cells) by direct hybridization with bar-coded probes, without prior amplification required for cloning and sequencing and any unknown errors this may lead to. Moreover, because TCR sequencing involves random clone selection, of which a limited number may be feasibly sequenced, it is prone to both over-and underrepresenting clonotype frequencies in a given population of cells. Finally, the readout of the DTEA technique is the number of transcripts for each probe, therefore depicting the true frequency of the different TCR genes or chains found in an unmanipulated sample. Figure 5 . DTEA simultaneously tracks TCRVa and Vb usage after adoptive T-cell therapy. TCRVa (A) and TCRVb (B) gene usages in TIL172 were compared. TCRVa22 and Vb4-3 were highly expressed in this sample, with frequencies of 45.15% and 44.17%, respectively. C, the expression patterns of TCRVa22 and Vb4-3 in PBMCs at different times after adoptive transfer were similar. TCRVa (D) and Vb (E) gene usage in peripheral blood of patient 117 at 2 weeks after TIL infusion were compared. TCRVa13-2 and Vb7-2 were highly expressed in this sample, with frequencies of 85.12% and 82.35%, respectively. F, similar usage patterns for TCRVa13-2 and Vb7-2 in TIL and PBMC at different times after infusion.
Identifying specific TCR chain usage from tumor-specific T-cell populations may reveal new TCR sequences that can be cloned and expressed in recombinant form, producing a new tumor-specific usage for adoptive cell transfer (28, 34) . DTEA can rapidly assess TCRVa and Vb usage of even low frequency clonotypes and potentially predict TCR pairing. It may therefore be a valuable tool for the determination of specific antitumor TCRs suitable for cloning and subsequent genetic modification of T cells. Available approaches to identifying paired TCRab-chains rely on T-cell staining with specific TCRVa or Vb antibodies and subsequent analysis using flow cytometry. By sorting T cells expressing specific TCR Va/Vb pairs, the hypervariable CDR regions of both chains can be sequenced after gene cloning. However, a major limitation of this approach is the lack of antibodies recognizing many specific TCRVa or Vb proteins. In contrast, DTEA uses probes specific for all currently known TCRVa and Vb mRNA species enabling detection of all TCRVa and Vb genes simultaneously. Using DTEA, we found that certain TCRVa-and Vb-chains were expressed at similar frequencies in a given TIL population, suggesting possible pairings of these chains. This observation was made from a wide range of TILs from different patients and different Va/Vb combinations could be predicted in the samples.
Different T-cell clones may share the same TCRVb gene but have a different CDR3 sequence, a region that interacts with antigenic peptides bound to MHC molecules. As of now, human T cells are known to express 48 TCRVb genes, but investigators have identified or predicted a much larger number of CDR3 sequences (6) . TCR cloning not only identifies TCRVb usage but can also determine CDR3 diversity within the same Vb-chain (9, 10, 36) . In contrast, DTEA cannot distinguish T-cell clones that have the same TCRVb, but different CDR3 sequences because the probes are specific for a given V region of each TCRVa and Vb. This distinction may also explain the differences in the calculated frequencies of the same TCRVb detected using DTEA versus the cloning methodology. Classical TCR gene cloning/sequencing of CDR3 could thus be considered as a complementary approach to DTEA. We do not intend for DTEA to be a substitute for DNA deep sequencing of genomic TCRVb loci that can identify thousands of unique Vb and CDR3 sequences in populations of T-cells. However, DTEA can readily aid investigators seeking a rapid, inexpensive, and nonlaborious method to measure TCRVa and Vb usages. DTEA also complements deep sequencing and cloning/ sequencing by first identifying the families of TCRVa and Vb genes that are expressed enabling a focused and indepth analysis by deep sequencing efforts to identify TCR usage in individual T-cell clones.
We speculate that DTEA will also prove valuable in other situations in which rapid, reliable, and highly sensitive monitoring of the TCRVa and Vb gene usage is warranted, such as in patients who receive vaccinations, elderly patients, patients with autoimmune diseases and infections, and recipients undergoing hematopoietic stem cell transplantation. The single copy number sensitivity of DTEA will enable identification of a wide range of possible TCR clone frequencies, including those with frequencies as low as 1 in 1,000 when sufficient T cells are analyzed. Such low frequency clones associated with these TCR genes can later become dominant clones in different pathophysiologic states.
DTEA may thus provide insight into whether T-cell clones emerge from endogenous T-cell reconstitution or expand from a rare TIL present in the transfused cell populations following lymphodepletion and infusion of TIL. DTEA may be able to detect and monitor epitope spreading whereby the immunogenicity of a given immune target expands because of tissue damage resulting in the expansion of T cells (and the associated TCR usage) not initially engaged. In this case, the appearance of new highly expressed TCRVa and Vb genes in blood samples may be a first indication of the expansion of new T-cell clones due to epitope or antigen spreading.
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